Business Context and Reporting Period
Company: OptimizeRx Corporation (a development stage company)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended June 30, 2010
Business Overview: The Company operates a direct-to-consumer business strategy focused on healthcare cost management. Key platforms include OPTIMIZERx.com (patient savings portal), OFFERx (pharmaceutical offer fulfillment), ADHERxE (patient engagement), and SampleMD (direct-to-physician sample distribution). The Company is classified as a smaller reporting company and a development stage enterprise.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 |
|---|---|---|
| Revenue | $18,003 | $4,720 |
| Operating Expenses | $1,155,177 | $1,731,766 |
| Net Loss | $(1,135,870) | $(1,702,868) |
| Net Loss Per Share (Basic & Diluted) | $(0.09) | $(0.14) |
| Cash and Cash Equivalents (End of Period) | $1,132,928 | $1,338,109 |
| Working Capital | $531,739 | Not explicitly stated |
| Total Assets | $2,451,866 | Not explicitly stated |
| Total Liabilities | $620,772 | Not explicitly stated |
Cash Flow Summary (Six Months Ended June 30, 2010):
- Operating Activities: Net cash used of $902,556.
- Investing Activities: Net cash used of $129,660 (primarily website development and license fees).
- Financing Activities: Net cash provided of $1,508,750 (primarily from the issuance of Series B Preferred Stock).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased nominally from $4,720 in the prior year period to $18,003, representing a 281% increase, though absolute volume remains low.
- Expense Reduction: Operating expenses decreased by approximately 33% year-over-year (from $1.73M to $1.16M), driven by reduced advertising and consulting fees.
- Improved Loss Position: Net loss decreased by 33% year-over-year (from $1.70M to $1.14M), reflecting the reduction in operating expenses.
- Capital Structure: The Company issued 15 shares of Series B Preferred Stock for $1.5 million in cash during the period. Additionally, a related party payable of $570,000 was recorded for the acquisition of patent rights (SampleMD) via stock options and future common stock.
- Asset Base: Total assets increased significantly from $890,142 (Dec 31, 2009) to $2,451,866 (June 30, 2010), largely due to the capitalization of patent rights ($974,762) and website development costs.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary & Outlook:
- Management believes the OPTIMIZERx database will be a significant revenue stream over time but notes that monetization has been minimal due to the short time since acquiring the majority of members.
- The Company is focusing on the SampleMD platform to address low patient adherence and redemption rates. A Master Services Agreement was signed with Walgreens Health Initiatives in July 2010.
- Liquidity Warning: Management explicitly states that as of June 30, 2010, the Company has insufficient cash to operate at current levels for the next twelve months. Continued operations are contingent upon obtaining additional financing.
Risks and Contingencies:
- Going Concern: The financial statements include a "Going Concern" note (Note 12) highlighting substantial losses since inception and dependence on future capital raises.
- Related Party Transactions: Significant transactions occurred with related parties, including a $570,000 payable for patent rights and $570,000 in related party accounts payable.
- Preferred Stock Obligations: Series A Preferred Stock is required to be redeemed on September 5, 2010. Series B Preferred Stock is redeemable on June 30, 2011. Both carry 10% cumulative dividends.
Investor Verification Checklist
- Cash Runway: Verify the Company's ability to raise additional capital immediately, as management admits insufficient cash for the next 12 months.
- Preferred Stock Redemption: Confirm the Company's plan to fund the redemption of Series A Preferred Stock due September 5, 2010.
- Revenue Realization: Assess the timeline for monetizing the 2 million member database and the SampleMD platform, given current revenue is negligible ($18k for six months).
- Related Party Payables: Review the terms and repayment schedule for the $570,000 related party payable recorded for the SampleMD patent rights.
- Stock Dilution: Monitor the impact of outstanding warrants (3,000,000 from Series B issuance) and convertible preferred stock on future share count.